Search filters
Filters
Clear All

Phase

  • 5
  • 30
  • 1
  • 7
  • 1
  • 5
  • 49
  • 27
  • 49

Found 49 Solid Tumors trials

A listing of Solid Tumors medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

NP-G2-044 as Monotherapy and Combination Therapy in Patients With Advanced or Metastatic Solid Tumor Malignancies

99 years or below
All genders
Phase 1
NP-G2-044 Monotherapy Primary Objectives The primary objectives for patients receiving NP-G2-044 monotherapy are the following: - To identify the recommended Phase 2 dose (RP2D) of continuously dosed NP-G2-044 monotherapy (Mono-RP2D) and characterize its safety; and - To assess preliminary signals of NP-G2-044 anti-tumor efficacy when administered as continuously dosed monotherapy. …
Learn More

UPCC 33922: An Open-Label Multicenter Study of LOXO-435 (LY3866288) In Advanced Solid Tumor Malignancies With FGFR3 Alterations

99 years or below
All genders
Phase 1
Please refer to Protocol LOXO-FG3-22001, Section 1.1.1 (Objectives and Endpoints) Please refer to Protocol LOXO-FG3-22001, Section 1.1.1 (Objectives and Endpoints) Please refer to Protocol LOXO-FG3-22001, Section 1.1.1 (Objectives and Endpoints)
Learn More

UPCC 04122 A Phase 1 Open-Label Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors

99 years or below
All genders
Phase 1
Please refer to Protocol Section 3 (Objectives and Endpoints). Please refer to Protocol Section 3 (Objectives and Endpoints). Please refer to Protocol Section 3 (Objectives and Endpoints).
Learn More

UPCC 06918:A Phase 1a/1b Study Exploring the Safety and Tolerability of INCB081776 in Participants With Advanced Solid Tumors

99 years or below
All genders
We are requesting to rely on WIRB as IRB of record for this study. This Study has 2 parts. The purpose of the Part 1 is to try to find the best dose of INCB081776 alone for patients who have advanced cancer. The purpose of Part 2 is to find …
Learn More

UPCC 14920 A Phase 1b First-in-Human Dose Escalation and Expansion Study of XMT-1536 In Patients with Solid Tumors Likely to Express NaPi2b

99 years or below
All genders
Phase 1
First-in-human, Phase 1b/2 safety study of the antibody-drug conjugate (ADC) XMT-1536 administered as an IV infusion once every four weeks. Patients with tumor types likely to express NaPi2b were enrolled in dose escalation. Patients with platinum-resistant ovarian cancer and non-small cell lung cancer (adenocarcinoma subtype) are being enrolled in the …
Learn More

A Phase 1/2a Open-Label Safety Pharmacokinetic and Preliminary Efficacy Trial of Oral ATRN-119 in Patients with Advanced Solid Tumors (AR-276-01)

99 years or below
All genders
Phase 1
The study will evaluate the safety profile of escalating doses of continuous daily oral ATRN-119 and to determine the maximum tolerated dose (MTD) and recommended dose. ATRN-119 is a drug that has been developed to treat cancers by taking advantage of genetic mutations found only in the tumor and not …
Learn More

UPCC 12922: An Early Phase Study to Evaluate the Safety Tolerability Pharmacokinetics and Preliminary Antitumor Activity of PEEL-224 in Patients with Advanced Solid Tumors

99 years or below
All genders
Phase 1
Please refer to Protocol Section 2 (Study Objectives and Endpoints). Please refer to Protocol Section 2 (Study Objectives and Endpoints). Please refer to Protocol Section 2 (Study Objectives and Endpoints).
Learn More

UPCC 32922: A Phase 1 First-in-Human Study of IK-930 an Oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects With Advanced Solid Tumors

99 years or below
All genders
Phase 1
Please refer to Protocol, Section 1.1.3. (Study Objectives and Endpoints) Please refer to Protocol, Section 3. (Objectives and Endpoints) Please refer to Protocol, Section 3. (Objectives and Endpoints)
Learn More

UPCC 03920: A Phase 1/1b Open-label Dose-escalation and Dose-expansion Study of TPST-1120 as a Single Agent or in Combination with Systemic Anti-Cancer Therapies in Subjects with Advanced Solid Tumors

99 years or below
All genders
Phase 1
This is a Phase 1 study that will evaluate the effectiveness of TPST-1120. Subjects may receive TPST-1120 alone or in combination with nivolumab. Subjects eligible to participate are those with advanced solid tumors.
Learn More

UPCC 35922: Phase 1/2 Safety and Efficacy Study of NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors

99 years or below
All genders
Phase 1
Please see Protocol NUV-868-01, Section 3 (Objectives and Endpoints) Please see Protocol NUV-868-01, Section 3 (Objectives and Endpoints) Please see Protocol NUV-868-01, Section 3 (Objectives and Endpoints)
Learn More
1 - 10 of 49